Quantcast
Channel: Bio-Dreck – BuyersStrike!
Viewing all 165 articles
Browse latest View live

A Hazy Shade of Winter – Part 1 (TYME)

$
0
0

Back in March 2012 a wretched Siesta Key, FL shell company called Global Group Enterprises (GGET) was born out of the offices of Diane J. Harrison.

globalgroups1

Diane is well known among fans of small cap stock scams, and to the SEC. She has the rare honor of being one of the few lawyers ever chastised for their role in aiding, abetting, and perpetrating stock frauds.

The SEC’s complaint alleges that attorney Diane J. Harrison, Esq. and her husband, Michael J. Daniels, both of Palmetto, Florida, manufactured at least five microcap issuers with the undisclosed intent to sell them based on their status as public companies with purportedly unrestricted shares available for resale in the public markets. According to the complaint, Daniels and Harrison created the false appearance that the companies were pursuing specific business plans with independent management and shareholders by installing friends and family (including defendant Catherine A. Bradaick-Zolla of Sarasota, Florida, who also provided other assistance to the fraud) as purported officers and shareholders.

and that’s not all:

The SEC’s complaint also alleges that Harrison participated in a separate fraudulent scheme involving at least 11 undisclosed blank check companies secretly controlled by Alvin S. Mirman and Sheldon R. Rose. The SEC previously filed enforcement actions against Mirman and Rose, who were also convicted of criminal charges and sentenced to prison based on the same alleged conduct. According to the SEC’s complaint, Harrison provided at least 21 false legal opinion letters in furtherance of Mirman and Rose’s scheme.

Read the full complaint here.

The shell was ostensibly run by Andrew Keck, whose wife, Sarah Keck, ran another Harrison scam, Neutra Corp (NTRR).

Not long after, in February 2013, control of the shell was bought by Ed Tobin, Christopher Brown and the fine folks at GEM Advisors (aka Global Emerging Markets aka GEM Group etc.) in NYC. Only now, the company has moved from one dirty lawyer, to another.

GGET2013-10k-gottbetter.png

Yes, our good friend, and ex-convict, Adam S. Gottbetter. Readers might recall his Very Bad Day.

Fast forward to 2015, and the GGET shell merges with a private bioturd, creating TYME. Naturally there is a press release to trumpet the good news. Perhaps the contact name will ring a bell?

tyme-rags

Indeed, it’s the Big Ram himself, part of any sell side whore dream team. Most famous for his relentless shilling of Ampio (AMPE).

Funny that his resume doesn’t show his moonlighting:

ragsresume

Nor does his CRD:

tyme-rags-crd

 

Or does it? It turns out Rags was fired from not one, but two, bucket shops for failing to disclose his lucrative side business!

FIRM DISCOVERED THAT INDIVIDUAL APPARENTLY HAS BEEN ACTING AS THE INVESTOR RELATIONS CONTACT FOR A PUBLIC COMPANY IN COMPENSATION FOR WHICH HE HAD RECEIVED SHARES OF COMMON STOCK IN THE COMPANY, ALONG WITH CASH PAYMENTS. NEITHER THE IR ROLE NOR OWNERSHIP OF THE SHARES AND CASH PAYMENTS WERE DISCLOSED TO THE FIRM

Read the full CRD here to learn more.

Just how lucrative? How about 250,000 shares and over $8k a month, for a part-time gig hyping reverse merger trash.

RagsFees.png

With two dirty lawyers and a dubious sell side whore working IR, just wait until we dig into the “trial” of TYME’s magic pill and its “results”.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

A Hazy Shade of Winter – Part 2 (TYME)

$
0
0

As we explored in Part 1, the provenance of Tyme Technologies (TYME) is hardly encouraging. We have a saying at BuyersStrike! HQ, “Past is prologue, always” but some might argue that past association with notorious scam lawyers Diane Harrison and Adam Gottbetter, along with a shady IR/bucket shop shill, Raghuram Selvaraju, doesn’t reflect the amazing potential of Tyme’s cancer treatment, SM-88.

Quite the contrary, Tyme’s past completely predicts Tyme’s nonsense treatment, its poorly designed trials, and its terrible efficacy.

SM-88 is actually a combination of four compounds, three of which are already approved drugs, easily available.

Sirolimus aka Rapamune (rapamycin)

Dilantin (phenytoin)

Uvadex (methoxsalen)

and

“Magic” Tyrosine (a modified form of Tyrosine, a non-essential amino acid)

Rapamune and related drug Afinitor are already used in oncology. So is Uvadex. Dilantin was once commonly prescribed to brain cancer patients for seizure suppression, but there have not been any reports of improved outcomes with Dilantin therapy.

With 2 known, and potentially 4 active compounds in this cocktail, one would think a study should have at least two arms:

  1. SM-88 arm (R+D+U+mT)
  2. R+D+U arm (active comparator)

Or better yet, to be considered well designed, at least 8 arms:

  1. SM-88 arm
  2. Rapamune only arm
  3. Dilantin only arm
  4. Uvadex only arm
  5. R+D+U arm
  6. R+D arm
  7. R+U arm
  8. D+U arm

Let’s see what clinical trials the good people at Tyme are actually running.

A quick search on Clinicaltrials.gov shows four studies. Two are recruiting, two are not yet recruiting.

First up is study NCT02562612, a breast cancer study entitled, simply, “Study of SM-88 in Advanced Cancers“. This study was announced in 2015, but as of today is still not enrolling.

Tyme-BC-Study-recruit.png

According to the company, the goal of the study is:

To assess the response rate and PFS in previously treated breast cancer patients. Additional objectives include the pharmacokinetics of multiple ascending doses of SM-88, a cocktail combination of 4 drugs being developed for the indication of metastatic breast cancer. Secondary objectives of this study include an assessment of safety and tolerability of ascending doses of orally administered SM-88. Additional response data will also be collected.
“The response rate compared to what?”, one may ask. Why, compared to nothing of course. This is a single arm open-label trial. Otherwise known as bullshit.
Tyme-BC-Study-Open.png
The next study on the list is NCT03778996, “SM-88 as Maintenance Therapy for Advanced Ewing’s Sarcoma”. This study also is not yet recruiting. And, it may come as no surprise that this study also is bullshit, it is an open-label trial comparing SM-88 to absolutely nothing.
Tyme-ES-StudyDesign.png
The third study of SM-88 is in prostate cancer.  This study, NCT02796898, was announced in 2016, and is currently recruiting patients. Any guesses as to blinding? Presence of a control group?
Tyme-PC-Study.png
Of course not! Just more bullshit.
That brings us to the last study on our list, NCT03512756. The pancreatic cancer study, which hopes to enroll 115 patients. The company will most certainly be hyping the early results of this study on a conference call Friday the 18th of January, 2019.
Let’s look at the study design:
Tyme-PS-Study.png
Seems a bit better than the other three, they actually claim this study is single blinded. But what, exactly, is being blinded? What is the difference between the groups?
tyme-2arms
As it turns out that while there are two arms in this trial, both arms are getting SM-88. They are only comparing SM-88 to more SM-88 and blinding only the central lab radiologists, who review the PET scans, as to which dose the patients are receiving.
The stated primary outcome measure of this study is:
Overall response rate (complete response + partial response) by central review of modified RECIST 1.1 using blinded independent central review (BICR) of radiological scans.
Don’t forget this last part, it will be important when we next analyze the TYME “results”.
THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

 

 

A Hazy Shade of Winter – Part 3 (TYME)

$
0
0

Today’s the day. The day a filthy reverse merger bioturd called Tyme Technologies hosts a conference call to discuss the early results from it’s ongoing study of SM-88, a cocktail of 3 already approved drugs plus their magic Tyrosine.

We’ve already examined the birth of TYME, and its relationship to not one, but two, sanctioned lawyers and one moonlighting sell side shill, in Part 1, here. We’ve also looked at the four clinical trials testing SM-88, and learned that not a single one is truly legitimate. These “studies” have neither control arms nor double-blinding. Read more about them in Part 2, here.

Right now let’s look at the early data for the pancreatic cancer study, NCT03512756. It can be found in this abstract.

tyme-results

So, although the original study plan was for 115 participants, as of September 2018 the company had only managed to enroll 36.

Of these 36 subjects, only 83% (30/36) remained on treatment. What happened to the other 6?

Of the 30 that remained on treatment, only 16 were “evaluable” for CTC (Circulating Tumor Cell) blood testing. What happened to the other 14?

Of the 16 that received CTC tests, 11 showed reductions. Sounds impressive, but something is off about this. Nowhere in the clinical trial record does it actually mention CTCs as being an outcome measure! The only listed outcome measure of this study is Overall Response Rate using RECIST 1.1:

tyme-outcome

The abstract continues, mentioning that 2 of 9 subjects showed CA19.9 (a tumor marker for pancreatic cancer) declines. But CA19.9 is not an outcome measure. And where did this group of 9 patients come from? What happened to the others?

Less and less patients seem to be available as the abstract continues. Only 6 were eligible for the initial scheduled assessment. And 3 of 4 had what the company called “RECIST or PET SUV responses”.

What happened to the other 2 out of 6? And why the change from using only RECIST as the outcome measurement? PET SUV is not part of the study protocol. One can be sure that if the patients actually had a true RECIST response, PET SUV would never have been mentioned.

One can expect the scum behind this biodreck to hype these results, 3/4 = 75% ORR using their bucket shop math, but the real number, if one wanted to look at this data in the most favorable light possible is that only 3/36 patients had a measurable response.

36 patients enrolled

30 patients remained on treatment

16 patients were evaluable for CTC – Not a real, specified, outcome measure.

9 patients evaluable for CA19.9 – Not a real, specified, outcome measure.

6 patients made it to initial assessment

4 patients were actually evaluated

3 patients had a response using a non-standard criteria not in the clinical trial plan

3/36. That’s 8.3%. In an unblinded study. And even then, the study is so poorly designed it is impossible to tell which agent, or agents, had any activity.

Fail.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

 

A HAZY SHADE OF WINTER QUICK TAKE – PART 4 (TYME)

$
0
0

A few weeks ago we looked at the Tyme Technologies (TYME) “study “of their magic tyrosine cocktail, SM-88 (aka SMK, aka snake oil) in pancreatic cancer, catch up with that here.

Today, the jokers at TYME gave us all a little Valentine’s Day gift, interim “results” from their uncontrolled, open-label, tiny n, prostate cancer “study.”

One can find details on this terribly designed study, officially titled “Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer” here NCT02796898.

In today’s press release, the company declares: “TYME Reports Encouraging SM-88 Clinical Results”. In prostate cancer one easy metric is the patient’s PSA score. A declining PSA score is good. An increasing PSA score is bad. Says the company:

PSA levels generally remained stable during treatment.

That’s not actually encouraging at all. Now, here are the results that actually matter, from the poster.

TYME-PSA

Again “After 3 cycles of therapy (12 weeks), median PSA increased 40.2% from 6.4 to 9.0.” a 40% increase is NOT remaining stable.

FAIL.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

Quick Take – What’s in a name? (THCT)

$
0
0

Presenting just one aspect from the curious case of Vegas based, pink sheet stinker, THC Therapeutics (THCT), or is it Millenium Blockchain, or is it Millenial Weedscam? No matter what, it was, is and always will be a fairytale. As of today, the 5th of April 2019, a $220mm vape dream.

THCTNameChanges

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

 

 

Quick Take – FDA delays Zogenix’s plan to poison children, sell side shill responds. (ZGNX)

$
0
0

Today after the bell, #fakeinnovation company Zogenix (ZGNX) announced that the FDA issued a “Refusal to File” letter for their recent NDA for “Fintepla“. This is absolutely the correct decision. Why?

Because Fintepla is not a new drug at all. It is #fakeinnovation. Fintepla is just a new brand name for a very dangerous drug that was taken off the market in 1997 for causing horrific heart valve problems in adults. That drug? Fenfluramine, aka Pondimin, aka the “Fen” in “Phen-Fen“.

Somehow the idiots at ZGNX thought 22 years later nobody would remember, and it would be a good idea to repurpose the drug and offer it to children. Guess not.

And the bigger idiots, of course, are the sycophantic sell side shills, like this moron, Danielle “Shill” Brill from Piper Jaffray.

ZGNXShill

After news like this she drops her price target from $72 all the way down to $68. As we say here at BuyersStrike! HQ, “hoes gots to eat too!”

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

 

 

 

Here’s where the story ends – (TWST)

$
0
0

Fans of 80s/90s jangle pop might recall Harriet Wheeler and her band The Sundays singing about “that little souvenir of a terrible year”, fans of Silicon Valley corporate shenanigans should take note of this little souvenir,

ThumbDrive

as it plays a key role in the strange story of high flying Silicon Valley company Twist Biosciences (TWST).

Twist, which currently sports a nearly $930mm valuation, was an October 2018 IPO. The shares have been marching steadily higher over the last month, heading into the lockup expiration on the 29th of April. Investors must not have read the prospectus closely, or at all.

Much like bioturd Organovo (ONVO), Twist uses all sorts of biotech buzzwords (“oligonucleotides”, “synbio”, “synthetic DNA”, “NGS” and our favorite here at BuyersStrike! HQ “leverage e-commerce to scale the genomics business“) to hide what is really just an inkjet printer business. Yes, that is what Twist actually does. Fancy inkjets that print DNA. Instead of CMYK colored ink, the Twist machines spit out adenine (A), cytosine (C), guanine (G) and thymine (T) inks.

It is true that selling fancy ink for fancy inkjet printers can be a good business. Just ask Hewlett Packard (HPQ) and its spinout Agilent (A). Asking Agilent in particular about Twist, its founders, and its employees, would be very wise.

Let’s examine the history of Twist, some of its officers and learn about that little souvenir from an angry former employer…

2000 – Eric Marc Leproust begins working at Agilent (A).

2007 – Eric Marc Leproust changes his name to Emily Marine Leproust.

LeProustEmily-Eric

November 2011 – While still working at Agilent, Emily Leproust agrees to become CEO of startup Twist.

February 2012 – Emily Leproust registers the Twistbioscience.com domain name.

February 2013 – Twist Biosciences is formally incorporated in Delaware and registered in California. See incorporation paperwork signed by Emily Leproust here.

April 2013 – Emily Leproust leaves Agilent. But not before taking that little souvenir:

LeproustSouvenir

July 2013 – Twist raises a Series A round.

August 2013 – Twist files two provisional patent applications. Siyuan Chen is one of the authors.

November 2013 – Siyuan Chen leaves Agilent to work at Twist.

August 2014 – Twist files its core patent application consolidating the two provisional patent applications from the year prior. Siyuan Chen is one of the authors.

February 2015 – The core TWST patent is published by the USPTO.

TwistPatent

June 2015 – Solange Glaize leaves Agilent to join TWST as CFO. But before she left, she also took a souvenir or two. According to Agilent:

glaizecomplaintexcerpt

February 2016 – Agilent sues Twist Biosciences and Emily Leproust for misappropriation of trade secrets.

January 2017 – Boston based Ginkgo Bioworks acquires synthetic DNA fancy inkjet printing company Gen9.

October 2017 – Solange Glaize is terminated as CFO of TWST.

October 2018 – Twist goes public, disclosing the existence of the Agilent suit and significant customer concentration risk. 32% of revenues for Q1-3 2018 were from Ginkgo Bioworks. The company sells 5.75mm shares.

Twist-IPO-Lockup

December 2018 – Agilent files its second amended complaint against Twist, Leproust, Glaize, and Chen.

In the suit we see a list of USB souvenirs that the Twist crew took from Agilent.

Souvenirs

Read the lawsuit carefully. It appears to be an open and shut case of industrial espionage and IP theft.

February 2019 – Twist reports fiscal 1Q19 results. Ginkgo revenues were only $2.7mm and forecast to continue to decrease. Most telling, ex-Ginkgo, the average synthetic bio order size went down 45%. Losses for the year will be higher than previous guidance at $92$94mm. This will leave Twist with about one year’s worth of cash entering 2020. Just in time for the Agilent jury trial to begin.

Don’t worry, though, Emily will make it up on volume as they “leverage ecommerce to scale the genomics business”, like this:

TwistCoupon

April 29, 2019 – Lockup restrictions come off of over 21mm shares.

TwistIPOLockupShares

Look out below!

Next time, a look at Twist‘s real business fundamentals and a similar Silicon Valley case from the 90s…..

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

What to listen for on the Twist CONference call. – (TWST)

$
0
0

This afternoon, April 30th, after the close, Twist Biosciences Fancy Inkjet Printing Services (TWST) will be announcing results for Fiscal 2Q19. There will be a conference call at 4:30pm NY times. Here are the details for those interested:

Call in number: 866-688-0947 – Call in code: 2244119
Replay number: 404-537-3406 – Replay code: 2244119

What will we at BuyersStrike! HQ be listening for on the call?

  1. Are gross margins still negative? Are you still losing money on every sale?
  2. How are those coupons working out? Are they helping the company “leverage ecommerce to scale the genomics“?
  3. Are losses increasing Q/Q? Y/Y?
  4. What are sales to their biggest customer, Ginkgo Bioworks (34% of revenues in FY18)? And are they still declining (Q1 2019 sales were $2.7mm)?
  5. What is the average order size ex-Ginkgo? Is that order size still going down (last quarter the average order size ex-Ginkgo declined 45%)?
  6. How many actual biotech/pharma customers do they have? What % of revenues is to the health care segment (16% in 2018, down from 20% in 2016!)?
  7. What % of revenues is to the industrial chemicals segment (59% in FY18)? You see, Twist isn’t really even a healthcare/biotech company at all. It is really little more than an inkjet print shop for various industrial chemical companies. 
  8. What is the estimated cash burn for FY19? Is it higher or lower than previous guidance? (Last quarter the company increased it’s guidance for cash burn by over 8mm).

If any reader does manage to get on the call and ask a question, may we suggest “Have you found those little USB thumb drives Agilent is seeking?

What’s that, you ask? Read up on Twist and the little USB souvenirs here.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

Quick Take – You were all warned about Puma. – (PBYI)

$
0
0

In what should come as no surprise to anyone with a clue, Neratinib aka Nerlynx, from former bucket shop biotech analyst Alan Auerbach‘s Puma Biotechnology (PBYI) has been a complete failure in the marketplace. In September 2016 readers were all warned this would be the case. As our friend @b4uconsent pointed out almost 3 years ago:

It’s a snore of a TKI (PD-1/PD-L1s are becoming old news, and investors are supposed to get amped about a TKI?) that perpetuates fear mongering to patients who don’t understand recurrence risk, it de-prioritizes QOL, and it indulges a wasteful healthcare system where anything other than gross inferiority must equate clinical benefit. But who’s going to prescribe this? Who’s going to take it?

and

there is a risk of “life-threatening” side effects when, per the 92% DFS rate at two years, the cancer itself is not life-threatening

and

Neratinib is a drug no one needs or asked for

Alan, and mentor Lindsay R, merely got lucky with Cougar, nothing more. In this instance, prophecy did not fail. Puma did.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR. 

Reg S(pider): Spidergoats, Spiderworms, Spiderscams Part 1 – (NXB, ENSRF, KBLB)

$
0
0

We have a saying at BuyersStrike! HQ, that “past is prologue“, and given the recent, insane, move in spider silk web spinning penny stock scam Kraig Biolabs (KBLB), it is a great time to take a look back into the history of spider silk stocks.

KBLB has had a remarkable run over the last month. The company now (as of the 15th of May 2019) sports a greater than $350mm market cap. Not bad for a tired retread of an old story.

KBLBChartMar19

Back in late 2000, there was a red hot deal in Canada. In fact, up to that point, this deal was the largest life sciences IPO in Canadian history. A small company, Nexia Biotech raised $40mm CAD. It’s product? Recombinant spider silk. What’s that, one asks?

Spider silk has long been recognized as being the strongest naturally produced fiber, but spiders are notoriously ill-tempered. It is hard to convince them to produce silk on demand and in quantity. The answer? Recombinant spider silk, which is spider silk produced by organisms other than spiders. The genetic sequence that codes for spider silk protein is inserted into the DNA of some other organism, which then produces the silk proteins.

Nexia’s solution? Spider-goats. Mostly goat, partly spider. Nexia’s big asset was a herd of transgenic GMO spider-goats.

NexiaIPO

In the IPO the company did warn investors that the fundamental patents would expire in 2014.

Nexia made lots of announcements. In 2001 they announced a deal with German entity IPK, to make spider silk in spider-potatoes and spider-tobacco plants.

Nexia-IPK-plants.jpg

In 2002 they announced that they had created recombinant spider silk fibers in conjunction with the US Army.

NexiaArmy

It turns out that making spider silk isn’t as easy as people had thought. In early 2003 the company began to pivot to using the transgenic goat technology to produce drugs, not spider silk.

A recombinant version of BChE, such as Protexia(TM), is essential since plasma derived sources would not be sufficient. Using its transgenic goat technology, Nexia plans to develop bioactive Protexia(TM) in large quantities, thus making it practical, for the first time, to protect large numbers of people from chemical weapons.

By May 2003 Nexia started to downsize:

NexiaCostReduction

In January 2005 the company sold all of the “Protexia” assets to Pharmathene, nka Altimmune (PIP nka ALT). In May 2005 the company was delisted from the TSX. In January 2006 the company morphed into the next hot thing, an oilfield services company, and became Enesco (ENS aka ENSRF). And finally, in 2015 the company had finally gone bankrupt.

ENS-bk

So, with that as prologue, let’s move on to Kraig.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR. 

 

Reg S(pider): Spidergoats, Spiderworms, Spiderscams Part 2 – (KBLB, Gregg Jaclin)

$
0
0

In Part 1, following our theme that “past is prologue“,  we looked at the history of Nexia Biotech, an older recombinant spider silk company, that quickly pivoted to transgenic drugs for biodefense, that then became an oil field services company, Enesco, which finally managed to go bankrupt.

In Part 2, please keep in mind another saying at BuyersStrike! HQ, “pedigree counts“.

Soon after the failure of Nexia’s transgenic spider-goats, and the transformation of Nexia into an oil company in 2006, a new spider silk player emerged. In early 2006 a small company was incorporated in Wyoming. Having raised no money from legitimate venture capitalists, in 2007 this start-up, Kraig Biocraft Laboratories, filed an SB-2 for an honest-to-goodness penny stock offering. Shares were being offered at a mere 3c! The company was not even going to receive any of the proceeds, all of the shares were being sold by existing shareholders.

The two men responsible for this abomination? Kim Thompson, CEO and sole director, and a name that should be familiar to penny stock scam fans, superstar shell factory lawyer Gregg Jaclin:

Sb2CoverpageKBLB

Read about Gregg’s penny stock exploits in this piece by Teri Buhl. Jaclin was busted by the Feds in 2017:

GreggJaclin

read more about Gregg’s troubles here.

Kraig’s business? Recombinant spider silk. From the SB-2 filing:

The Product
It has long been known that certain fibers produced in nature possess unique mechanical properties in terms of strength, resilience and flexibility.  These protein based fibers, exemplified by spider silk, have been the subject of much interest to materials scientists.
We believe that the production of  recombinant protein based polymers in commercial quantities holds the promise of a material, which is lighter, thinner, more flexible, and tougher than aramid fibers. Other applications include use as structural material for aircraft, and for any application in which light weight and high strength are required.
While the properties of spider silks are well known, there is presently no known way to produce the fibers in commercial quantity.  The spiders are cannibalistic, and can not be raised in concentrated colonies.
The Technology
While scientists have been able to replicate the proteins that are the building blocks of spider silk, the technological barrier that has stymied production, is the incapacity to form these proteins into a fiber with the desired mechanical characteristics.
We have acquired the right to use the patented genetic sequences and genetic engineering technology developed in two university laboratories.  Our technology builds upon the unique advantages of the discoveries made within the university system.  The university technology, in collaboration with our own concepts and leadership, form the foundations of our research and product development.
We are working to use this genetic engineering technology to create recombinant protein based polymers.  Management is committed to steering the research toward the development of commercial production of spider silks, spider silks analogs and new polymers composed of recombinant proteins. The goal is to create recombinant fibers for use in the technical textiles market.
The inventor of this technology concept, Kim Thompson, is the founder of Kraig Biocraft Laboratories, Inc.

That last sentence bears repeating:

The inventor of this technology concept, Kim Thompson, is the founder of Kraig Biocraft Laboratories, Inc.

Really? Kim Thompson is the inventor of recombinant spider silk? Funny, his resume doesn’t mention any prior experience at Nexia, nor any other relevant experience either with spiders, or with silk.

KIM THOMPSON, 46, President, CEO, and Director Mr. Thompson was a founder of the California law firm of Ching & Thompson which was founded in 1997 where he specialized in commercial litigation.  He has been a partner in the Illinois law firm of McJessy, Ching & Thompson since 2004 where he also specializes in commercial litigation.   Mr. Thompson received his bachelor’s degree in applied economics from James Madison College, Michigan State University, and his Juris Doctorate from the University of Michigan.

Maybe Kim was moonlighting all of those years, maybe the company has tons of patents either assigned to it, or still held by Kim? Buried in the filing is this gem:

THE COMPANY HAS NO PATENTS OR DESIGN PATENTS ON ANY OF ITS PRODUCTS IN DEVELOPMENT.
At this time, the Company has no patents or design patents on any of its products in development.  As a result, there is a possibility that the Company’s products could be imitated or directly manufactured and sold by a competitor.  It is also possible that some or all of the Company’s research, development ideas and proposed products are covered by patent rights held by some other entity.  In that event, the Company could incur devastating liability and be forced to cease operations.

Fast forwarding to today, nearly 12 years later, KBLB still has exactly 0 US Patents. From the recent 10K:

License Agreements/Intellectual Property
We have obtained certain rights to use a number of university created, and patented, spider silk proteins, gene sequences and methodologies.
Between 2010 and 2014 the University of Notre Dame filed approximately twelve patent applications pursuant to our intellectual property and collaborative research agreement.  Under the terms of that agreement the Company has an option for the exclusive commercial rights to that technology. The Company has notified the University of its exercise of that option.   These patent applications include coverage in the United States, Europe, South Korea, Vietnam, Brazil, India, China, Australia, Japan, and Canada.  As of the date hereof, two patents have been issued, number 10-1926286 in South Korea and number 2011314072 in Australia, all remaining patents applications are still in process.
As it turns out, the fundamental University of Wyoming recombinant spider silk patents, from 1995, have already expired. The most accomplished researcher in the field, and the actual developer of the technology is Randy Lewis. Randy has long moved on from spider-goats, and now is at the University of Utah working on coaxing alfalfa and corn to product spider silk. And silkworms? Yeah, he has a patent application pending on those too.
Pedigree counts.
Next time, we’ll look at the current run-up in KBLB shares, the money behind the company, and examine some of the company’s recent public statements.
THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR. 

Reg S(pider): Spidergoats, Spiderworms, Spiderscams Part 3 – (KBLB, GALE, CYTR, Michael McCarthy)

$
0
0

To recap our continuing series on Kraig Biocraft Labs (KBLB), in Part 1, we looked at the history of another spider-silk company, the originator of the field, Nexia Biotech.

In Part 2, we uncovered the involvement of filthy crim lawyer Gregg Jaclin, in foisting this penny stock onto the public markets, and the non-involvement of Kraig CEO Kim Thompson in developing any spider-silk technology whatsoever.

Today let’s explore just how, where, and from whom, Kraig gets its money.

Kraig has recently touted an “investment” from the University of Notre Dame:

However, what really happened is that KBLB didn’t have the cash to pay the school what it has owed the University for YEARS, in return for the technology the company has licensed. An agreement, by the way, that ended in 2017.

On June 6, 2012, the Company entered into a consulting agreement for intellectual property and collaborative research and development with The University of Notre Dame.  On March 4, 2015, the Company entered into a new collaborative research agreements (2015 Notre Dame Research Agreement)  extending the duration of the agreement through March 2016; in February 2016 the agreement was extended to July 31, 2016.  Under the agreement the Company will provide approximately $534,000 in financial support. In May 2017 this agreement was amended to increase the total funding by approximately $189,000 and the duration of this agreement was extended to September 30, 2017. The Company did not extend the agreement after September 30, 2017. As of December 31, 2018 no new agreement has been signed.

Not able to pay off the school, Kraig did a debt-for-equity swap. Notre Dame did increase their equity position, but this is not a vote of confidence, rather an admission that Kraig will never have the money to pay off the debt.

Although Nexia was the biggest life sciences IPO in Canadian history up until that point, and other competitors in the spider silk world, like Bolt Threads, have raised huge sums of venture financing (and a partnership with Patagonia), tiny KBLB has, instead, resorted to financing of the ugliest kind, with the most unseemly of “investors”.

Like the company’s long time benefactor, filthy death spiral-like, future-priced, schlock shop Calm Seas:

On July 17, 2009, we entered into letter agreement for an Equity Line of Credit with Calm Seas Capital, LLC, which was amended on September 14, 2009 (together, as amended, the “Letter Agreement”).
Pursuant to the Letter Agreement with Calm Seas Capital, during a 24 month period we may put to Calm Seas up to an aggregate of $1,000,000 in shares of our Class A common stock for a purchase price equal to 80% of the lowest closing “bid” price of our Class A common stock during the five consecutive trading days immediately following the date we deliver notice to Calm Seas of our election to put shares pursuant to the Letter Agreement.  We may only put shares at the beginning of each calendar month, unless Calm Seas accepts an additional put

and again:

On October 2, 2014, the Company entered into a letter agreement for an equity line of financing up to $7,500,000 (the “Letter Agreement”) with Calm Seas Capital, LLC (“Calm Seas”).
Under the Letter Agreement, over a 24 month period from the effective date of a registration statement covering shares issuable to Calm Seas (the “Effective Date”), we may put to Calm Seas up to an aggregate of $7,500,000 in shares of our Class A common stock for a purchase price equal to 80% of the lowest price of our Class A common stock during the five consecutive trading days immediately following the date we deliver notice to Calm Seas of our election to put shares pursuant to the Letter Agreement.  We may put shares bi-monthly.

Just who is Calm Seas Capital, LLC?

Who is Calm Seas? The infamous Michael McCarthy.

That’s right. Calm Seas Capital, LLC is actually one of the filthiest stock operators of the last 10 years, Michael McCarthy. Probably better known for his “Dream Team Group” alter-ago, he is a vertically integrated stock scammer. One might remember him from such bioturds as Galena (GALE now SLS) CytRx (CYTR), and Lion Bio (LBIO now IOVA).

McCarthy’s M.O.? His Calm Seas outfit invests in scam companies, getting stock a big discount and selling it off to retail suckers. Some of the money the company raises from Calm Seas is required to be spent on IR/PR services provided by none other than Michael and his cronies.

Read about how his companies would pay people to post tout pieces on the internet, most notably on Seeking Alpha. And read about how he got caught. Read about what the Feds think.

Adam Feuerstein, now at Stat, and Richard Pearson have both written extensively on GALE, CYTR, DreamTeam, McCarthy, and the scams they were pulling.

More recently, in March 2019, the company resorted to an older form of financing for scams, Reg S, which seems to be slowly coming back into vogue. Read more about Reg S scams here.

The press release from Kraig was light on details. It merely says:
Under the terms of the stock purchase agreement, the Company issued shares of its class A common stock at a price of $0.06758 per share and warrants to purchase additional shares of its class A common stock at exercise prices of $0.06 and $0.08.

One needs to dig into the filings to get any real information:

On March 9, 2019, Kraig Biocraft Laboratories, Inc. (the “Company”) entered into a purchase agreement with one investor (the “Purchase Agreement”). Pursuant to the Purchase Agreement, the Company issued the investor 14,797,278 Units at a purchase price of $0.06758 per Unit, for total gross proceeds to the Company of $1,000,000. The Units consist of 14,797,278 shares of the Company’s Class A Common Stock (the “Common Stock”) and two warrants (the “Warrants”): (i) one warrant entitles the investor to purchase up to 14,797,278 shares of Common Stock at an exercise price of $0.06 per share (the “6 Cent Warrants”) and (ii) one warrant entitles the investor to purchase up to 7,398,639 shares of Common Stock at an exercise price of $0.08 per share (the “8 Cent Warrant”). The Warrants shall be exercisable at any time from the issuance date until the following expiration dates:
● ½ of all 6 Cent Warrants shares shall expire on March 8, 2021;
● ½ of all 6 Cent Warrants shall expire on March 8, 2022;
● ½ of all 8 Cent Warrants shall expire on March 8, 2022; and,
● ½ of all 8 Cent Warrants shall expire on March 8, 2023.
The securities sold in the private placement were issued in reliance on an exemption from registration under Regulation S of the Securities Act of 1933, as amended (“Regulation S”)
Typically in these deals the “one investor” is actually a boiler room somewhere outside of the United States that then pushes these shares on retail idiots. Usually, when it is a package of shares and warrants, the shares are immediately sold off, and the warrants are kept, enabling the boiler room owner to profit handsomely. Why? Because the warrants have great value. Using Black-Scholes the 6c warrants were actually worth 4c at issuance. The 8c warrants were worth 1.5c at issuance.
In return for $1mm, the buyer received a package worth:
  • 14,797,278 shares, when the stock was trading at 6c = $887,836
  • 14,797,278 Warrants struck @ 6c (each worth 4c) = $591,891
  • 7,398,639 Warrants at struck @ 8c (each worth 1.5c) = $110,979
which equals $1,590,706, an immediate 59% profit. A profit that is substantially higher after the run in KBLB shares over the past month. The identity of the Reg S buyer is still unknown, but there are a grand total of 0 legitimate Reg S investors. Maybe Michael is hiding out overseas somewhere?
THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

When Worlds Collide (TWTR, KBLB)

$
0
0

While the BuyerStrike! Twitter account remains in Twitter Jail time-out for daring to use the “t-word” (n.b. “tard“), the SJW Twitter police have no issues with spam accounts that hype DreamTeamGroup/Michael McCarthy affiliated (S)pider Con Kraig Biocraft (KBLB), such as this one.

KBLB-Spam-TwitterKeep up the good work there @Jack and your Tard Team.
THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

Quick Take – How NOT to do a “study”– SOLY

$
0
0

Anyone waiting for the stock scammers at Soliton (SOLY) to run an actual study on anything, should take a look at the Clinicaltrials.gov record for their tattoo removal “studies”.

Count the red flags in the Study Design section:

SOLY-study-design

N=12. Single group. No masking (completely unblinded).

Hmm, and just how are the 12 patients selected for this study?

soly-inclusion

They are the exact same patients from the previous “trial”! If the treatment actually worked, why would they need to come back a year later and enroll in yet another trial?

Any tells for bullshit in the locations section?

SOLY-Study-Site

Just a single center.

How about the investigator running the trial?

SOLY-Study-PI

Does that name seem familiar? It should be.

Capelli

He’s also the President of SOLY.

The next “study” will certainly be just as scam-tacular.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

 

When is a ‘Clinical Trial’ not a clinical trial 2.0? (ECTE, SOLY)

$
0
0

Back in 2011, readers learned about a worthless bio-turd named Echo Therapeutics (ECTE) (or was it Sontra? Or Choicetel?) and the games it was playing to trick investors into believing it was running legitimate clinical trials.

Read about its unlisted, unregistered, “trials”, here.

Now, almost 8 years later another turd, Soliton (SOLY) is trying the same old tricks. Hard to decide whom is stupider? Management for using the same tired scam playbook, or investors for falling for it over and over again.

On April 9th of this year, the company issued a press release (one of many since the company went public in a filthy Reg scAm deal in late February 2019) about its completed ‘clinical trial’ for cellulite treatment. (This happens to be an indication where there are several competing devices already on the market in the USA.) Says the company:

soly-cellulite-trial

Just as we asked with ECTE, “when is a ‘Clinical Trial’ not a clinical trial?” When you cannot find it on Clinicaltrials.gov perhaps? A search of the Clinicaltrials.gov database, try it yourself here, yielded only two hits (see here) for any studies sponsored by Soliton (SOLY). Neither of which have anything to do with cellulite. More bullshit from con artists. SOLY=FAIL.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

 

 


Another day, another shameless PR stunt by Soliton (SOLY)

$
0
0

Walter Klemp and his klown krew are at it again this morning, with a new breathless press release from his Soliton (SOLY) Reg scAm stock promotion (read more about Soliton’s amazing 10K here, its ridiculous excuse for a clinical study here, and its completely undocumented, unregistered, trial here). Today the company supposedly announced a “significant discovery” about using its machine for cellulite treatment. A machine that isn’t actually available for sale.

SOLY-Cellulite

Most breathlessly, the company exclaims that it believes the RAP “is a potentially important new way to treat cellulite and improve the appearance of the skin.” Oh really? Funny that a simple search shows up multiple better funded, better managed companies offering devices right now, and clinics that have been treating patients for years.

There is the Cellactor from Storz Medical from Switzerland:

Stoltz-Cellulite

And the D-Actor device, also from Storz:

Storz-dactor

Then there’s the ZWave from Germany’s Zimmer, which has been used to treat cellulite since at least 2012!

Zimmer2

And one can buy a ZWave Pro today! Even on Ebay.

ZimmerEbay

Of course, one can also buy SOLY share certs today, and isn’t that the real product here?

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

 

 

 

 

 

 

Quick Take – The Honest Crook (SOLY)

$
0
0

Ever wonder just who is being paid to tout Reg scAm turd Soliton (SOLY)? One of the websites pushing the stock is nasdaqstocks.com. The front page is basically just a billboard for SOLY.

nasdaqstocks

Drill down into any of the stories on SOLY and you will discover that the innocently named Nasdaqstocks.com site is just a tout vehicle, named, logo’d, and colored to deceive.

SOLY-Tout

Millionaire Media, LLC, although registered in Nevada, is actually run out of a nondescript single family home in Middletown, RI.

aquidneck

Interestingly enough, Millionaire Media LLC has actually had its registration revoked by the State of Nevada.

MillMediaRevoked

The guy behind Millionaire Media, LLC? A resourceful chap named Ahmed A. Alomari.

What sets Ahmed apart from run-of-the-mill touts and stock market scoundrels is that if you look at the disclaimer on his Nasdaqstocks.com website, you’ll find a refreshing burst of honesty.

SOLY-Disclaimer

On this we can all agree.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

Soliton Covering Their Tracks? (SOLY)

$
0
0

Two weeks ago, on May 31st, we looked at SOLY‘s rather bizarre, undocumented, “clinical trial” for their RAP device.

In an obvious attempt to cover their tracks, on June 10th the company hastily registered a trial into the government’s Clinicaltrials.gov database.

SOLY-TrialCYA

Naturally, this being a Reg scAm bioturd, the “trial” is a complete joke. Just 5 patients, no control arm, and no blinding.

SOLY-CelluliteTrialDesign

And just as naturally, for a stock promotion, two days later, on June 12th, SOLY put out a press release announcing that the results from this PoC Cellulite Trial would be presented in July!

SOLY-TrialResultsPR1

SOLY’s Walter Klemp and his krim klown krew sure are busy beavers. From listing the study to announcing the upcoming announcement of results in just 2 days. Maybe they can give Enron Linda a hand with the NWBO trial.

Odd that Wally can promise 26 week trial data in mid July for a trial that didn’t exist, according to government records, before the 10th of June.

Of course all of this just stock promotion window dressing. 510(k) devices are not approved for indications, they are “cleared”, and no trials are actually needed for 510(k) devices. Which is good, because what SOLY calls “trials” are just content creation exercises for shameless stock promotion.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

The Company You Keep (SOLY, GOPH)

$
0
0

While researching the various low rent stock promoters hired to pump ridiculous Reg scAm stinker Soliton (SOLY), one can imagine the sheer joy at BuyersStrike HQ! when we discovered that Soliton is using one of the same firms that a year ago was touting Russian mob stinker Gopher Protocol (GOPH) (read more about GOPH here, here, and here).

Let’s see what Wally Klemp and his band of morons have been up to in their continuing quest to pump up their stock.

Here’s a tout page on SOLY:

FNM-Soly-Tout

And from the disclaimer:

FNM-Soly-Disclaimer

FNM is FN Media, a South Florida outfit run by one-time real estate broker Patrick Grimm. They operated a now dormant site, marketnewsupdates.com , during the GOPH promotion:

WayBackFNM-Goph

During the GOPH promotion, FN Media was located in Coral Gables, FL:

FNMOldAddress

Here’s a pic of their office:

FNMediaCoralGables

In December 2018, FN Media moved to 49 N. Federal Highway #281 in Pompano Beach, FL.

FNMediaNewAddressPompano

The new spot is a real upgrade to their digs. Check out the new office:

FNMediaPompanoPic

Mr. Grimm seems to have gotten his start in the stock scam business at least 10 years ago, with a Miami company called Wall Street Capital Funding, LLC:

PatrickGrimm-WSCF

WSCF, which touted tons of scams, was eventually busted by the Feds:

WSCF-SEC

Whether Russian mob nonsense or Texas me-too medical devices, remember the saying, “frauds of a feather flock together”!

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

 

 

 

Quick Take – The Best S1 Excerpt You Will Read All Month (BSGM)

$
0
0

The amazing fourth incarnation of an old electrocardiogram scam, BioSig Technologies (BSGM), currently sports a $185mm market cap. It should be no surprise that the investors suckers piling into the stock never read the filings, or if they do, they don’t go back to the original, effective, S1. For if anyone did, they would notice a curious omission:

s1-mgmt-bsgm

there is no CEO. Not many promising companies access the public markets without a Chief Executive Officer. Further perusal reveals they HAD a CEO:

DrachmanCEOTenure

David Drachman. He lasted all of two months. Wonder what happened to him? Read on:

On January 7, 2014, David Drachman, our former chief executive officer and president, filed a statement of claim against us with the American Arbitration Association with respect to his resignation from his positions with us in November 2013.  Mr. Drachman alleges, among other things, that (i) we misled him with respect to the status of our technology and required him to perform capital raising duties that had not been previously agreed upon, (ii) he resigned from his positions with us for good reason, as such term was defined in his employment agreement with us, and (iii) he, in his individual capacity, has full rights to the ownership and control of a patent application describing a combined ablation and recording unit directed at the use of electrocardiography sensing for control of radio frequency renal denervation that we filed with the U.S. Patent and Trademark Office during the time Mr. Drachman served in his positions with us. More specifically, the statement of claims filed by Mr. Drachman alleges that all or a majority of the engineering documentation and technical files that Mr. Drachman believed to be necessary for our product development and manufacturing had not been developed, as opposed to statements made by representatives of our company that, in Mr. Drachman’s opinion, indicated that such necessary documentation and files had been developed.  The statement of claims filed by Mr. Drachman additionally alleges that we made statements to him and potential investors concerning the PURE EP System based on our proof of concept animal study results, as opposed to the results from a study performed with a prototype of the PURE EP System and that we withheld the substantive results of our proof of concept animal study from both Mr. Drachman and potential investors. Mr. Drachman alleges that the highly limited information that he received led him to doubt that the actual performance of the PURE EP System would be consistent with the statements about the product that we made to him and potential investors.

Let’s break this down. The CEO of the company quits after two months on the job and alleges the following:

  • The company misled him with respect to the status of our technology.
  • The engineering documentation and technical files that Mr. Drachman believed to be necessary for product development and manufacturing had not been developed, as opposed to statements made by representatives of the company.
  • The company made statements to him and potential investors concerning the PURE EP System based on proof of concept animal study results, as opposed to the results from a study performed with a prototype of the PURE EP System.
  • The company withheld the substantive results of the proof of concept animal study from him and potential investors.

Leading Drachman to doubt that the actual performance of the PURE EP System would be consistent with the statements about the product made to him and potential investors.

They aren’t just scamming investors, they were also conning the guy brought in to be the CEO straight man in the con. He just figured it out before things got out of hand.

Or as we say around here at HQ, the founders of BioSig are full of BioShit.

And that arbitration case? Settled, with the company paying off ex-CEO Drachman.

BSGM-SettlementDrachman

There’s more smoke, and a lot more searing hot fire at BSGM. Stay tuned.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.
Viewing all 165 articles
Browse latest View live




Latest Images